In 90% of cases of amyotrophic lateral sclerosis, the cause is unknown. Although various
mechanisms are likely involved in pathogenesis, evidence for the relevance of each to motor …

Investigators reported that for ALS patients, dexpramipexole produced a dose-dependent
slowing of decline in function over three months in a double-blind trial, and a trend toward …

As yet, there is no staging system for amyotrophic lateral sclerosis (ALS). One early attempt
to define disease stages consisted of post-hoc analysis of the international, placebo …

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive disease of motor neurons,
resulting in worsening weakness of voluntary muscles until death from respiratory failure …

Patients with symptoms suggestive of a progressive neurologic disease, such as
amyotrophic lateral sclerosis (ALS), usually seek an initial medical consult to obtain a …

with bulbar onset, 35% of placebo-treated patients were still alive compared with 73% of
riluzoletreated patients; whereas for the limb-onset patients, 64% of placebo-treated patients …

Background: Riluzole is currently the only Food and Drug Administration–approved
treatment for ALS, but its effect on survival is modest. Objective: To identify potential …

Since the approval of riluzole for the treatment of amyotrophic lateral sclerosis (ALS) 17
years ago, more than 30 large clinical trials have been conducted, but none has proved …

ALS is a progressive motor neuron disease with no effective treatment. The anti-excitotoxic
drug riluzole (100 mg/day) has been shown to decrease mortality and muscular …

The ALS clinical trial landscape is currently highly active with several promising innovative
developments and therapeutic options. By further refinement of evidence-based guidelines …